Zoetis Launches Portela® (relfovetmab) in Canada and the European Union
Zoetis announced the commercial launch of Portela (relfovetmab) in Canada and the European Union, the first long-acting anti-NGF monoclonal antibody therapy for cats providing up to three months of osteoarthritis pain relief per injection. The product offers a differentiated dosing schedule compared to the company's existing Solensia (monthly), aiming to improve compliance and address underdiagnosis in feline osteoarthritis.
Key figures
- Drug Name
- Portela (relfovetmab)
- Oa diagnosis rate
- 18%
- Duration of effect
- three months
- Oa prevalence cats
- 40%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.